Emcure Pharmaceuticals delivered robust financial results for Q3FY26, with revenue growing 20.4% year-on-year to ₹2,363 crore and profit after tax surging 48.2% to ₹231 crore. As reported by GuruFocus, the company's domestic business recorded 15% year-on-year growth, driven by strong performance across key therapies including cardio, CNS, and oncology segments. International markets showed even stronger momentum with 24.5% growth, led by Europe's significant 29.6% increase driven by the ramp-up of new products. However, the company faced some margin pressure with gross margins declining slightly to 59.3% from 60.1% due to the unlicensing of the Sanofi OAD portfolio and changes in business mix.
Emcure's semaglutide brand Poviztra, launched in December through an exclusive partnership with innovator Novo Nordisk, continues to gain momentum through strategic celebrity partnerships. The company launched a campaign called Winning Over Obesity, partnering with celebrities like M.S. Dhoni and Neha Dhupia, as well as social media influencer-doctors like Dr Tanaya Narendra to raise awareness about obesity. According to Mint, Samit Mehta, executive director of operations at Emcure, explained that the approach aims to create a robust patient support system with a helpline, nutritional counselling and usage guidance. Poviztra is a semaglutide injection available as a once-weekly pen device in five strengths: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and a maintenance dose of 2.4 mg, priced competitively starting at roughly ₹2,200 a week, or ₹8,790 per month.
Despite strong growth, Emcure faces potential headwinds from increased competition in the semaglutide market, which could affect future market share and profitability. The company also encountered a one-time exceptional expense of ₹38 crores related to labor code changes, impacting financial results. According to GuruFocus, there is potential for increased competition in the semaglutide market, which could affect future market share and profitability. The company's net debt increased to ₹1,200 crores, primarily due to the payout for Juventus minority stake. Additionally, gross margin pressure from the faster-growing international business compared to the domestic business could continue to impact overall profitability.
Emcure is leveraging its strong presence in cardiology, following its partnership with Sanofi for key cardiac brands, to reach more doctors in that segment. The company entered an exclusive partnership with Novo Nordisk to launch an innovative drug in the semaglutide category, enhancing its product portfolio and market position. According to Mint, experts believe that the massive popularity of weight loss drugs and their perception as lifestyle drugs will reshape the marketing landscape for drugmakers. Sujay Shetty, PwC global health industries advisory leader, told Mint that the market growth potential for GLP-1s is vast given that the drug is also being considered for various other health indications, though doctors caution against celebrity endorsements.
